Pandom%252520dsr

# Pandom DSR ## Overview Pandom DSR is a fixed-dose combination medication containing **Pantoprazole (40 mg)**, a proton pump inhibitor (PPI), and **Domperidone (30 mg)**, a dopamine (D2) receptor antagonist. It functions as a gastroprokinetic and acid-suppressing agent. ## Primary Indications * Gastroesophageal reflux disease (GERD). * Peptic ulcer disease. * Functional dyspepsia associated with delayed gastric emptying. ## Adult Dosing * **Standard Dose:** 1 capsule once daily. * **Administration:** Must be taken on an empty stomach, at least 30–60 minutes before the first meal of the day. * **Maximum Dose:** Do not exceed 1 capsule per 24 hours due to the prolonged release mechanism of domperidone and the risk of cardiac arrhythmias. ## Pediatric Dosing * **Not recommended.** The safety and efficacy of the sustained-release domperidone component have not been established in pediatric populations. Use of domperidone in children carries significant cardiac safety risks. ## Dose Adjustments * **Renal Impairment:** Pantoprazole dose adjustment is generally not required; however, domperidone should be used with caution. Dosing frequency may need to be reduced in severe renal impairment. * **Hepatic Impairment:** Use with caution. In severe hepatic impairment, the dosage of pantoprazole should not exceed 20 mg/day (Note: This formulation is fixed-dose; therefore, avoid this product in severe liver disease). ## Contraindications * Known hypersensitivity to pantoprazole, domperidone, or substituted benzimidazoles. * Conditions where cardiac conduction is impaired (e.g., prolonged QT interval). * Presence of underlying cardiac disease (e.g., congestive heart failure). * Gastrointestinal hemorrhage, obstruction, or perforation where gut stimulation is dangerous. * Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin). ## Adverse Effects * **Common:** Headache, dry mouth, diarrhea, abdominal pain. * **Serious:** Cardiac arrhythmias (QT prolongation/Sudden Cardiac Death—associated with domperidone), hyperprolactinemia (galactorrhea, gynecomastia), interstitial nephritis, and magnesium deficiency (long-term PPI use). ## Key Drug Interactions * **CYP3A4 Inhibitors:** Significantly increase domperidone plasma concentrations, increasing cardiac risk. * **pH-Dependent Drugs:** Pantoprazole reduces the absorption of drugs requiring acidic environments (e.g., ketoconazole, iron salts, atazanavir). * **Clopidogrel:** Potential reduction in the antiplatelet effect of clopidogrel (clinical significance remains debated). ## Monitoring * **Cardiac:** Monitor ECG if the patient has risk factors for arrhythmia. * **Electrolytes:** Periodic monitoring of serum magnesium during long-term therapy (>1 year). * **Prolactin:** Monitor for symptoms of hyperprolactinemia if utilized for extended periods. ## Clinical Pearls * **Cardiac Risk:** Domperidone is associated with an increased risk of serious ventricular arrhythmias and sudden cardiac death. It should be used at the lowest effective dose for the shortest duration possible. * **"DSR" Suffix:** The "SR" implies sustained release of domperidone; therefore, the capsule must be swallowed whole and never crushed or chewed. * **Deprescribing:** Re-evaluate the need for PPI therapy every 3–6 months. Avoid lifelong PPI use without a clear, documented clinical indication to mitigate risks of *C. difficile* infection, fractures, and malabsorption. *** *Disclaimer: This information is for educational purposes only. Clinical guidelines and local prescribing protocols vary; always verify current prescribing information, contraindications, and drug-drug interactions with official institutional or regulatory drug references before clinical application.*